Abstract
About a quarter of sclerodermic patients present calcinosis. However, patients with limited form of the disease are more likely to have calcinosis than patients with diffuse form. We report a case of a 54-year-old female patient with limited cutaneous scleroderma using rituximab (RTX) to treat lung fibrosis and arthritis. Into RTX treatment, she also had a complete resolution of calcinosis in her hands. The patient reported improvement in dyspnea and synovitis after two courses of RTX (four weekly infusions 375 mg/m2 each). After 7 months of the first infusion, the calcinosis in her fingers had a complete remission, especially the right thumb. Based on current evidences, we discuss the use of rituximab as a promising therapy to treat not only lung disease but also calcinosis in patients with scleroderma.
Similar content being viewed by others
References
Robertson LP, Marshall RW, Hickling P (2003) Treatment of cutaneous calcinosis in limited systemic sclerosis with minocycline. Ann Rheum Dis 62(3):267–269
Boulman N, Slobodin G, Rozenbaum M, Rosner I (2005) Calcinosis in rheumatic diseases. Semin Arthritis Rheum 34(6):805–812
Reiter N, El-Shabrawi L, Leinweber B, Berghold A, Aberer E (2011) Calcinosis cutis: part II. Treatment options. J Am Acad Dermatol 65(1):15–22, quiz 23–4
Slimani S, Abdessemed A, Haddouche A, Ladjouze-Rezig A (2010) Complete resolution of universal calcinosis in a patient with juvenile dermatomyositis using pamidronate. Joint Bone Spine 77(1):70–72
Daoussis D, Antonopoulos I, Liossis SN, Yiannopoulos G, Andonopoulos AP (2012) Treatment of systemic sclerosis-associated calcinosis: a case report of rituximab-induced regression of CREST-related calcinosis and review of the literature. Semin Arthritis Rheum 41(6):822–829
Haroon M, McLaughlin P, Henry M, Harney S (2011) Cyclophosphamide-refractory scleroderma-associated interstitial lung disease: remarkable clinical and radiological response to a single course of rituximab combined with high-dose corticosteroids. Ther Adv Respir Dis 5(5):299–304
Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C, Karampetsou M, Yiannopoulos G, Andonopoulos AP (2010) Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) 49(2):271–280
McGonagle D, Tan AL, Madden J, Rawstron AC, Rehman A, Emery P, Thomas S (2008) Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab. Rheumatology (Oxford) 47(4):552–553
Tashkin DP, Scleroderma Lung Study Research Group et al (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354(25):2655–2666
Daoussis D, Liossis SN, Yiannopoulos G, Andonopoulos AP (2011) B-cell depletion therapy in systemic sclerosis: experimental rationale and update on clinical evidence. Int J Rheumatol 2011(214013):7
Lafyatis R, Kissin E, York M, Farina G, Viger K, Fritzler MJ, Merkel PA, Simms RW (2009) B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 60(2):578–583
Chiu YE, Co DO (2011) Juvenile dermatomyositis: immunopathogenesis, role of myositis-specific autoantibodies, and review of rituximab use. Pediatr Dermatol 28(4):357–367
Edouard S, Sailler L, Sagot C, Munsch C, Astudillo L, Arlet P (2010) Un pouce douloureux (A painful thumb). La Revue de Médecine Interne 31:712–713
Bader-Meunier B, Decaluwe H, Barnerias C, Gherardi R, Quartier P, Faye A, Guigonis V, Pagnier A, Brochard K, Sibilia J, Gottenberg JE, Bodemer C (2011) Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French Autoimmunity and Rituximab registry. J Rheumatol 38(7):1436–1440
Disclosures
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
de Paula, D.R., Klem, F.B., Lorencetti, P.G. et al. Rituximab-induced regression of CREST-related calcinosis. Clin Rheumatol 32, 281–283 (2013). https://doi.org/10.1007/s10067-012-2124-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-012-2124-z